Metronidazol B. Braun

Metronidazole, the active ingredient in Metronidazol B. Braun, is a nitroimidazole antibiotic presented as an injection solution for intravenous use. It treats anaerobic bacterial infections and certain protozoal infections in both adults and children as prescribed by a healthcare professional.

GNH USA supplies Metronidazol B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metronidazole is employed to manage infections caused by anaerobic bacteria and susceptible protozoa.

Intra‑abdominal infections: eradicates anaerobic organisms, helping resolve infection and inflammation. Pelvic inflammatory disease: eliminates causative anaerobes, reducing pelvic pain and disease progression. Bacterial vaginosis: restores normal vaginal flora by targeting anaerobic bacteria. Sepsis caused by susceptible organisms: provides systemic antibacterial activity to control bloodstream infection. Bacterial meningitis (anaerobic pathogens): penetrates the central nervous system to treat meningitis caused by anaerobes. Protozoal infections (giardiasis, trichomoniasis, amebiasis): destroys protozoa, relieving gastrointestinal or genitourinary symptoms.

Metronidazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: occasional dull or throbbing pain. - Diarrhea: loose stools that may be self‑limiting. - Abdominal pain: cramping or discomfort. - Dizziness: light‑headed feeling.

Serious or Rare Side Effects: - Seizures: rare neurologic events, especially with high doses. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering. - Liver toxicity: elevated enzymes or hepatitis. - Blood dyscrasias: agranulocytosis or aplastic anemia.

Before initiating therapy, clinicians should consider several safety measures.

Assess renal function: adjust therapy in patients with severe renal impairment. Monitor for neurotoxicity: watch for seizures or peripheral neuropathy during treatment. Avoid use in first trimester: limited safety data suggest caution during early pregnancy. Use caution with alcohol: may provoke a disulfiram‑like reaction. Check for drug interactions: especially with warfarin, lithium, and cimetidine. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metronidazole can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Alcohol: may cause a disulfiram‑like reaction with flushing and nausea. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: can raise lithium concentrations, risking toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma levels. - Phenobarbital: may reduce metronidazole efficacy by inducing metabolism. - Bupropion: combined use may increase seizure risk.